OM336 in Seropositive Autoimmune Diseases
Recruiting now · Phase 1
Conditions studied: Sjogrens Disease, Idiopathic Inflammatory Myopathy (IIM)
In brief
An early-phase clinical trial evaluating the safety, tolerability, and pharmacokinetics of OM336 in adult participants with seropositive autoimmune diseases. OM336 is administered subcutaneously in ascending dose cohorts.
Key facts
- Study ID
- NCT07229144
- Run by
- Lakefront Biotherapeutics West LLC
- People needed
- 39
- Starts
- 2025-10-01
- Expected to finish
- 2028-03-01
- Last updated by the study team
- 2026-06-15
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Waikato Hospital — Hamilton, Waikato Region, New Zealand (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.